Chiavenna S M, Jaworski J P, Vendrell A
Ferrer Advanced Biotherapeutics, Ferrer Internacional, Barcelona, Spain.
Institute of Virology, CICVyA, INTA - CONICET, Castelar, Buenos Aires, Argentina.
J Biomed Sci. 2017 Feb 20;24(1):15. doi: 10.1186/s12929-016-0311-y.
Following Milstein's discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today, mAbs are being developed to target different molecules with different mechanisms of action and its target potential is unlimited. However, this huge and fast growing new field needs to be organized to better understand the treatment options we have to confront different cancer diseases. Current cancer targeted immunotherapies aim to achieve different goals like the regulation of osteoclast function, the delivery of cytotoxic drugs into tumor cells and the blockade of oncogenic pathways, neo-angiogenesis and immune checkpoints. Here, we reviewed the most relevant therapeutic mAbs for solid tumors available in current clinical practice.
在米尔斯坦的发现之后，单克隆抗体（mAbs）成为生物医学科学的基本工具。在癌症领域，自从第一种单克隆抗体被美国食品药品监督管理局（FDA）批准以来，取得了巨大的进展，使其在当前临床实践中成为许多癌症类型的一种治疗选择。如今，正在研发针对具有不同作用机制的不同分子的单克隆抗体，其靶向潜力是无限的。然而，这个庞大且快速发展的新领域需要进行整理，以便更好地理解我们应对不同癌症疾病所拥有的治疗选择。当前的癌症靶向免疫疗法旨在实现不同的目标，如调节破骨细胞功能、将细胞毒性药物递送至肿瘤细胞以及阻断致癌途径、新血管生成和免疫检查点。在此，我们综述了当前临床实践中可用的针对实体瘤的最相关治疗性单克隆抗体。
